| MeSH term | MeSH ID | Detail |
|---|---|---|
| Peri-Implantitis | D057873 | 1 associated lipids |
| Adrenocortical Adenoma | D018246 | 1 associated lipids |
| Hyperparathyroidism, Primary | D049950 | 1 associated lipids |
| Lithiasis | D020347 | 2 associated lipids |
| Labyrinthitis | D007762 | 2 associated lipids |
| Cholesteatoma, Middle Ear | D018424 | 2 associated lipids |
| Eye Neoplasms | D005134 | 2 associated lipids |
| Pasteurellaceae Infections | D016871 | 2 associated lipids |
| Dental Pulp Calcification | D003784 | 2 associated lipids |
| Hypertension, Pregnancy-Induced | D046110 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gomes SA et al. | RANKL is a mediator of bone resorption in idiopathic hypercalciuria. | 2008 | Clin J Am Soc Nephrol | pmid:18480302 |
| Ozkok A et al. | Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. | 2012 | Clin J Am Soc Nephrol | pmid:22490874 |
| Konduri K et al. | Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. | 2005 | Clin Lymphoma | pmid:15794867 |
| Zangari M et al. | Response to bortezomib and activation of osteoblasts in multiple myeloma. | 2006 | Clin Lymphoma Myeloma | pmid:17026821 |
| Jakob C et al. | Serum levels of total-RANKL in multiple myeloma. | 2009 | Clin Lymphoma Myeloma | pmid:19951882 |
| Kastritis E et al. | Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. | 2006 | Clin Lymphoma Myeloma | pmid:16879774 |
| Kim SW et al. | Effects of mushroom, Pleurotus eryngii, extracts on bone metabolism. | 2006 | Clin Nutr | pmid:16359759 |
| Arikan F et al. | Osteoprotegerin levels in peri-implant crevicular fluid. | 2008 | Clin Oral Implants Res | pmid:18081868 |
| Rakic M et al. | Bone loss biomarkers associated with peri-implantitis. A cross-sectional study. | 2013 | Clin Oral Implants Res | pmid:22708989 |
| Wang HL et al. | Protein biomarkers and microbial profiles in peri-implantitis. | 2016 | Clin Oral Implants Res | pmid:26424287 |
| Mamalis AA et al. | Chemical modification of an implant surface increases osteogenesis and simultaneously reduces osteoclastogenesis: an in vitro study. | 2011 | Clin Oral Implants Res | pmid:21070383 |
| Duarte PM et al. | Differential cytokine expressions affect the severity of peri-implant disease. | 2009 | Clin Oral Implants Res | pmid:19302394 |
| Durual S et al. | Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts. | 2011 | Clin Oral Implants Res | pmid:21087318 |
| Galli C et al. | GSK3b-inhibitor lithium chloride enhances activation of Wnt canonical signaling and osteoblast differentiation on hydrophilic titanium surfaces. | 2013 | Clin Oral Implants Res | pmid:22626030 |
| Graziani F et al. | The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. | 2006 | Clin Oral Implants Res | pmid:16584418 |
| Passeri G et al. | Adhesion pattern and growth of primary human osteoblastic cells on five commercially available titanium surfaces. | 2010 | Clin Oral Implants Res | pmid:20636730 |
| Pedrosa WF et al. | Immunohistochemical, tomographic and histological study on onlay bone graft remodeling. Part II: calvarial bone. | 2009 | Clin Oral Implants Res | pmid:19531103 |
| Spyrou P et al. | Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. | 2002 | Clin Oral Implants Res | pmid:12519337 |
| Pereira AC et al. | Histomorphometrical and molecular evaluation of endosseous dental implants sites in humans: correlation with clinical and radiographic aspects. | 2013 | Clin Oral Implants Res | pmid:22092653 |
| Koch FP et al. | Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. | 2012 | Clin Oral Investig | pmid:20938793 |
| Lossdörfer S et al. | PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. | 2011 | Clin Oral Investig | pmid:20697756 |
| Mozzati M et al. | Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. | 2013 | Clin Oral Investig | pmid:22864527 |
| Lossdörfer S et al. | Anabolic effect of intermittent PTH(1-34) on the local microenvironment during the late phase of periodontal repair in a rat model of tooth root resorption. | 2010 | Clin Oral Investig | pmid:19280233 |
| Ohe JY et al. | Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. | 2012 | Clin Oral Investig | pmid:21938481 |
| Kraus D et al. | Intermittent PTH(1-34) signals through protein kinase A to regulate osteoprotegerin production in human periodontal ligament cells in vitro. | 2012 | Clin Oral Investig | pmid:22186940 |
| Wolf M et al. | Potential role of high mobility group box protein 1 and intermittent PTH (1-34) in periodontal tissue repair following orthodontic tooth movement in rats. | 2013 | Clin Oral Investig | pmid:22777389 |
| Pereira GB et al. | Acute effects of resistance training on cytokines and osteoprotegerin in women with metabolic syndrome. | 2013 | Clin Physiol Funct Imaging | pmid:23383690 |
| Fábrega E et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. | 2006 May-Jun | Clin Transplant | pmid:16824158 |
| Sudrová M et al. | Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women. | 2011 | Clin. Appl. Thromb. Hemost. | pmid:20682598 |
| Shang M et al. | Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women. | 2013 | Clin. Biochem. | pmid:23531404 |
| Kim J et al. | Plasma osteoprotegerin levels increase with the severity of cerebral artery atherosclerosis. | 2013 | Clin. Biochem. | pmid:23726804 |
| Nezami N et al. | Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy. | 2010 | Clin. Biochem. | pmid:20727867 |
| Osorio A et al. | Mineral-bone metabolism markers in young hemodialysis patients. | 2011 | Clin. Biochem. | pmid:21933667 |
| Pilichou A et al. | High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. | 2008 | Clin. Biochem. | pmid:18355453 |
| Wittersheim E et al. | OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis. | 2006 | Clin. Biochem. | pmid:16530745 |
| Stępień E et al. | Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. | 2011 | Clin. Biochem. | pmid:21539822 |
| Sodi R et al. | The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism. | 2009 | Clin. Biochem. | pmid:19523465 |
| Karatolios K et al. | Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. | 2012 | Clin. Biochem. | pmid:22202560 |
| Kolahi S et al. | Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis. | 2010 | Clin. Biochem. | pmid:20034487 |
| Ibrahim T et al. | Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. | 2011 | Clin. Breast Cancer | pmid:21764390 |
| Fizazi K et al. | Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. | 2003 | Clin. Cancer Res. | pmid:12855635 |
| De Toni EN et al. | OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. | 2008 | Clin. Cancer Res. | pmid:18676739 |
| Lipton A et al. | Serum osteoprotegerin levels in healthy controls and cancer patients. | 2002 | Clin. Cancer Res. | pmid:12114435 |
| Chanda D et al. | Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. | 2009 | Clin. Cancer Res. | pmid:19920103 |
| Pearse RN | Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. | 2006 | Clin. Cancer Res. | pmid:17062713 |
| Yang M et al. | The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. | 2006 | Clin. Cancer Res. | pmid:16638872 |
| Nadiminty N et al. | Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. | 2006 | Clin. Cancer Res. | pmid:16533764 |
| Dougall WC | Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. | 2012 | Clin. Cancer Res. | pmid:22031096 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Brown JM et al. | Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. | 2001 | Clin. Cancer Res. | pmid:11595685 |
| Bhatia P et al. | Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. | 2005 | Clin. Cancer Res. | pmid:15671541 |
| Tsukamoto S et al. | Clinical significance of osteoprotegerin expression in human colorectal cancer. | 2011 | Clin. Cancer Res. | pmid:21270110 |
| Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
| Patiño-GarcÃa A et al. | Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. | 2009 | Clin. Cancer Res. | pmid:19671856 |
| Chan BY et al. | Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. | 2003 | Clin. Chem. | pmid:14633883 |
| Hill MD | What kind of stroke is it? | 2008 | Clin. Chem. | pmid:19042986 |
| Nybo M et al. | Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. | 2008 | Clin. Chem. | pmid:19042987 |
| Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
| Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Kauther MD et al. | Biochemical markers of particle induced osteolysis in C57BL/6 mice. | 2010 | Clin. Chem. Lab. Med. | pmid:20704528 |
| Shaarawy M et al. | Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure. | 2007 | Clin. Chem. Lab. Med. | pmid:17970704 |
| Halapas A et al. | Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction. | 2008 | Clin. Chem. Lab. Med. | pmid:18298349 |
| Philippou A et al. | Systemic cytokine response following exercise-induced muscle damage in humans. | 2009 | Clin. Chem. Lab. Med. | pmid:19445648 |
| Mesquita M et al. | Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. | 2009 | Clin. Chem. Lab. Med. | pmid:19676147 |
| Avbersek-Luznik I et al. | Increased levels of osteoprotegerin in hemodialysis patients. | 2002 | Clin. Chem. Lab. Med. | pmid:12476941 |
| Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
| Zhang N et al. | Relationship between age-related serum concentrations of TGF-beta1 and TGF-beta2 and those of osteoprotegerin and leptin in native Chinese women. | 2009 | Clin. Chim. Acta | pmid:19361465 |
| Wu XY et al. | Relationship between age-related reference values of serum osteoprotegerin and leptin in native Chinese women and compared with those in women of other races. | 2008 | Clin. Chim. Acta | pmid:18155666 |
| Wu XY et al. | The relationship between the levels of gonadotropic hormones and OPG, leptin, TGF-beta1 and TGF-beta2 in Chinese adult women. | 2010 | Clin. Chim. Acta | pmid:20478283 |
| Palazzuoli A et al. | Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: relation to coronary artery narrowing and plaques number. | 2008 | Clin. Chim. Acta | pmid:18328262 |
| Xie GQ et al. | Relationship between serum TGF-β1, OPG levels and osteoporotic risk in native Chinese women. | 2013 | Clin. Chim. Acta | pmid:23643930 |
| Yilmaz Y and Eren F | Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. | 2012 | Clin. Chim. Acta | pmid:22985537 |
| Casado-DÃaz A et al. | Individual single tube genotyping and DNA pooling by allele-specific PCR to uncover associations of polymorphisms with complex diseases. | 2007 | Clin. Chim. Acta | pmid:16999948 |
| Bosselut N et al. | Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. | 2013 | Clin. Chim. Acta | pmid:23022619 |
| Montecucco F et al. | The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? | 2007 | Clin. Dev. Immunol. | pmid:18320012 |
| Feng X et al. | Modulatory effect of 1,25-dihydroxyvitamin D 3 on IL1 β -induced RANKL, OPG, TNF α , and IL-6 expression in human rheumatoid synoviocyte MH7A. | 2013 | Clin. Dev. Immunol. | pmid:24348674 |
| Moran CS et al. | Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm. | 2010 | Clin. Endocrinol. (Oxf) | pmid:19438902 |
| Olmos JM et al. | Factors other than glucocorticoids are involved in the osteoblast activity decrease caused by tissue injury. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16487437 |
| Chailurkit LO et al. | Reduced attenuation of bone resorption after oral glucose in type 2 diabetes. | 2008 | Clin. Endocrinol. (Oxf) | pmid:18088395 |
| Kim SM et al. | Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. | 2005 | Clin. Endocrinol. (Oxf) | pmid:16268814 |
| Guang-da X et al. | Changes in endothelial function and its association with plasma osteoprotegerin in hypothyroidism with exercise-induced silent myocardial ischaemia. | 2008 | Clin. Endocrinol. (Oxf) | pmid:18410551 |
| Gannagé-Yared MH et al. | Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712667 |
| Rhee EJ et al. | The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712673 |
| Han KO et al. | The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15730418 |
| Ueland T et al. | A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. | 2009 | Clin. Endocrinol. (Oxf) | pmid:19508593 |
| Oh KW et al. | The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. | 2004 | Clin. Endocrinol. (Oxf) | pmid:15272921 |
| Oh KW et al. | Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15638876 |
| Hofbauer LC et al. | Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14725683 |
| Buzi F et al. | Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14678293 |
| Nagasawa T et al. | LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. | 2002 | Clin. Exp. Immunol. | pmid:12390325 |
| Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
| Lukić IK et al. | Alteration of newly induced endochondral bone formation in adult mice without tumour necrosis factor receptor 1. | 2005 | Clin. Exp. Immunol. | pmid:15654822 |
| Kiji M et al. | Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide. | 2007 | Clin. Exp. Immunol. | pmid:17550374 |
| Miyashita T et al. | Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. | 2004 | Clin. Exp. Immunol. | pmid:15270863 |
| Franchimont N et al. | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. | 2004 | Clin. Exp. Immunol. | pmid:15544627 |
| Guo L et al. | Effects of erythropoietin on osteoblast proliferation and function. | 2014 | Clin. Exp. Med. | pmid:23135151 |
| Canon JR et al. | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. | 2008 | Clin. Exp. Metastasis | pmid:18064531 |
| Roudier MP et al. | Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. | 2006 | Clin. Exp. Metastasis | pmid:16912914 |
| Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |